Articles with public access mandates - Amrita BasuLearn more
Not available anywhere: 1
Expanding the diagnostic toolbox for complex genetic immune disorders
ED Abrams, A Basu, MEZ Thomas, SE Henrickson, RS Abraham
Journal of Allergy and Clinical Immunology, 2024
Mandates: Chan Zuckerberg Initiative
Available somewhere: 9
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
BJCKK Amrita Basu, Ganesan Ramamoorthi, Gabriella Albert, Corey Gallen ...
Frontiers in Immunology, 2021
Mandates: US Department of Defense
Sequential anti-PD1 therapy following dendritic cell vaccination improves survival in a HER2 mammary carcinoma model and identifies a critical role for CD4 T cells in mediating …
KN Kodumudi, G Ramamoorthi, C Snyder, A Basu, Y Jia, S Awshah, ...
Frontiers in immunology 10, 1939, 2019
Mandates: US National Institutes of Health
Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway
Y Jia, KN Kodumudi, G Ramamoorthi, A Basu, C Snyder, D Wiener, ...
Molecular Therapy 29 (4), 1541-1556, 2021
Mandates: US Department of Defense, US National Institutes of Health
Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer …
C Rosemblit, J Datta, L Lowenfeld, S Xu, A Basu, K Kodumudi, D Wiener, ...
Oncotarget 9 (33), 23058, 2018
Mandates: US Department of Defense, US National Institutes of Health
Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities
G Ramamoorthi, K Kodumudi, C Gallen, NN Zachariah, A Basu, G Albert, ...
Seminars in cancer biology 78, 78-89, 2022
Mandates: US Department of Defense
Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma
G Ramamoorthi, K Kodumudi, C Snyder, P Grover, H Zhang, MI Greene, ...
Journal for Immunotherapy of Cancer 10 (6), 2022
Mandates: US Department of Defense, US National Institutes of Health
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine
A Basu, GK Albert, S Awshah, J Datta, KN Kodumudi, C Gallen, A Beyer, ...
Cancer immunology research 10 (1), 108-125, 2022
Mandates: US Department of Defense, US National Institutes of Health
Intercepting premalignant, preinvasive breast lesions through vaccination
NN Zachariah, A Basu, N Gautam, G Ramamoorthi, KN Kodumudi, ...
Frontiers in Immunology 12, 786286, 2021
Mandates: US Department of Defense
Refractory, fatal autoimmune hemolytic anemia due to ineffective thymic-derived T-cell reconstitution following allogeneic hematopoietic cell transplantation for hypomorphic …
JR Yonkof, A Basu, MT Redmond, AK Dobbs, L Perelygina, ...
Pediatric blood & cancer 70 (5), e30183, 2022
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program